OPKO Health (OPK) 8-K Submission of Matters to a Vote of Security Holders

General Overview

18 June 2015

Exhibit 99.3

Our

Vision

We

are

a

leading

specialty

pharmaceutical

company

To

be

the

leading

developer

and

supplier

of

highly

potent

pharmaceutical

products for

global

markets

Click

above

to

view

EirGen’s

expanded

facility

Ireland: Fact Sheet

Waterford

Cork

Dublin

•

Population

4.2

million

•

Largest

Exporter

of

Pharmaceuticals

in

the

World,

8

th

largest

producer.

9

of

World’s

Top

10

Pharma

Companies

Located

in

Ireland

•

Home

to

120

Pharma

companies;

33

pharma

and

biopharma

plants

are

FDA

approved.

25,000

direct

&

25,000

indirect

employees

serviced

by

excellent

university

programs

•

English

speaking

and

excellent

compliance

track

record

•

Waterford

is

situated

in

the

South

East

of

Ireland.

Population

of

50,000

people.

Business Overview

A Specialty

Pharmaceutical Company

Focused on the development and

commercial supply of highly potent

pharmaceutical products

In a purpose built, state of the art,

high containment facility

Introductions –

EirGen Founders

PATSY CARNEY

Chief Executive Officer/ Co-Founder

»

Co-founded EirGen

»

Previously Head of Operations and BD for IVAX Ireland (14 years)

»

Holds a BSc In Industrial Chemistry from University of Limerick

and an MBA from University of Limerick

TOM BRENNAN

Chief Technical Officer/ Co-Founder

»

Co-Founded EirGen

»

Previously held senior  technical positions with IVAX and Stada

»

10 Years IVAX Ireland as R&D Manager

»

Holds a BSc in Chemistry from Cork  IT, an MSc in Industrial Pharmacy

from University of Manchester and an MBA from University of Limerick

»

Qualified Person, Six Sigma Black Belt, Packaging Technologist

EirGen Key Milestones

2005

2006

2008

2009

2011

2012

2013

Successful

Regulatory Audit

OPEN FOR

BUSINESS

Submission of First

Pan EU EirGen

License

1.

1

st

License

Approval

in Canada

2.

5

th

Oncology

product

license submitted to

US FDA

3.

1

st

commercial

product launch in EU

1.

Two oncology product

licenses submitted to

Japanese PMDA

2.

US FDA facility

approval and product

approval

1.

Japanese PMDA

facility approval

and

1

st

product

approval

2.

US FDA

Inspection, zero

483’s

EirGen

Founded

Facility

expansion

complete

2014

1.

US FDA Inspection,

zero 483’s

2.

Soft-gel fitout

complete

3.

31

st

clinical

study

complete and passed

4.

10

th

ANDA

submitted

to

US FDA

2015

1.

5

th

IMB

(EMA) 

Inspection –

no

major

observations

2.

Acquisition by

OPKO Health

Current Position: where we are now

»

98 employees, all graduates

»

31 successful Clinical Studies

»

42 countries for commercial product supply

»

27 products in R&D

»

10 Products filed with US FDA to date, 3 approved

»

4

Pan EU CTD Dossiers filed to date and approved

»

5

Oncology Products filed with Japanese PMDA; 4 approved

Current Position: Regulatory Status

»

Global license submission strategy

»

FDA, Aug 2014, no 483’s

»

IMB (EMA), May 2015, no major observations

»

Licensed to handle Cytotoxic Materials

Therapeutic  Focus

»

Oncology Molecules

»

Immunosuppressants

»

Prostaglandins

»

Cytotoxic Molecules

»

Hormonals

»

Steroids

7

Global

Presence

Category

Countries

Commercial

(BLUE)

42

Licenses

Pending

(ORANGE)

20

Customer

Contracts

(GREEN)

85

EirGen Existing Business Model

R&D (non-

GMP and

GMP)

Clinical

studies and

license

approval

Routine on-

going

commercial

supply

Sales,

marketing &

distribution

Strategic Partner

EirGen OPKO Opportunities

»

API

Vertical

Integration

-

Synergies

with

OPKO

Finetech,

Israel

»

Product

Development

&

Manufacturing

-

OPKO’s

current

&

future

products

»

Irish

based

Supply

Chain

Hub

-

global

distribution

of

OPKO

Products

»

Tax

efficient

R&D

Hub

-

proven

R&D

track

record

since

incorporation

Thank You

www.EirGen.com